Accelerate Diagnostics Bolsa (NASDAQ: AXDX)

Últimas noticias sobre Accelerate Diagnostics (NASDAQ:AXDX) Bolsa

Accelerate Diagnostics

Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics Inc

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE&#x2122; system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.
The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.5 hours, enabling same shift targeted antimicrobial therapy for patients with serious infections.
With a user-friendly workflow, high throughput capacity, and scalable design, once approved by the FDA, the WAVE system will offer microbiology laboratories a comprehensive AST solution to meet a wide range of testing demands and hospital formulary needs.
According to the World Health Organization, sepsis affects an estimated 49 million people globally each year, resulting in approximately 11 million deaths.1&nbsp; Of those, around 1.32 million deaths2 are attributed to bacterial antimicrobial resistance. Sepsis also represents the most significant cost burden to the U.S. healthcare system, with an estimated annual expense of $62 billion.3
By delivering rapid AST results, the WAVE system is designed to support earlier, targeted antimicrobial therapy—improving patient outcomes, reducing hospital costs, and helping combat antimicrobial resistance.

Biotech

News

General

AXDX

Accelerate Diagnostics Submits Its Accelerate WAVE System And Positive Blood Culture Gram-Negative Test Kit To The U.S. FDA For 510(k) Clearance

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly sales of $2.800 million which missed the analyst consensus estimate of $3.020 million by 7.28 percent. This is a 7.50 percent decrease over sales of $3.027 million the same period last year.

Earnings

Earnings Misses

Accelerate Diagnostics Q4 Sales $2.800M Miss $3.020M Estimate

2024 Fourth Quarter and Full-Year Financial Results
<ul>
<li>Preliminary revenue was approximately $11.7 million for the year, compared to $12.1 million in the prior year. While year-over-year revenues for consumable products increased by approximately 3%, overall revenue was down year-over-year due to lower revenues from capital sales of Pheno instruments compared to the prior year. &nbsp;</li>
<li>Ended the year with approximately $16.3 million in cash and cash equivalents, compared to $20.9&nbsp;million at the start of the fourth quarter, a reduction in cash and cash equivalents for the fourth quarter of 2024 of $4.5 million. This reflects our continued reduction in operating cash use over the prior quarters of 2024.</li>
</ul>

Guidance

Accelerate Q4 Revenue Of $11.7 Vs $12.1M YoY, $16.3M Cash Ending 2024; 3% Rise In Consumable Revenue Amid Pheno Capital Sales Decline

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent. This is a 9.82 percent decrease over sales of $3.299 million the same period last year.

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR)
Enables rapid, automated microbial identification on the Bruker MALDI Biotyper&#xAE; CA System directly from positive blood culture samples
TUCSON, Ariz., Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper&#xAE; CA &nbsp;System (MBT-CA System) and MBT-CA Sepsityper&#xAE; software extension.
Designed for clinical laboratories, the Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification (ID) using Bruker's MBT-CA system. This eliminates the need for overnight culture methods, reducing the wait time for microbial ID results, which is critical in the fight against sepsis.
The Accelerate Arc system is designed to leverage the breadth of the Bruker MBT-CA reference library to provide rapid ID. This, in conjunction with our future rapid phenotypic antibiotic susceptibility testing (AST) innovation, the Accelerate WAVE&#x2122; system1, can enable same shift reporting to Antimicrobial Stewardship teams and clinicians alike. By providing clinicians with rapid ID and AST results, clinicians can get the patient on the optimal antibiotic therapy many hours sooner, which has been shown to improve patient outcomes with Sepsis, reduce antimicrobial resistance rates and hospital costs.

Accelerate Diagnostics Announces FDA Clearance Of Its Accelerate Arc System, An Automated Platform Designed To Fight Against Sepsis And Antimicrobial Resistance

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.55) by 9.09 percent. This is a 83.16 percent increase over losses of $(2.97) per share from the same period last year. The company reported quarterly sales of $2.99 million which missed the analyst consensus estimate of $3.01 million by 0.80 percent. This is a 2.23 percent increase over sales of $2.92 million the same period last year.

Earnings Beats

Accelerate Diagnostics Q2 EPS $(0.50) Beats $(0.55) Estimate, Sales $2.99M Miss $3.01M Estimate

Accelerate Diagnostics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) an innovator of rapid in vitro diagnostics in microbiology, announced the successful completion of its WAVE pre-clinical trial. The Accelerate WAVE system is designed to deliver rapid antimicrobial susceptibility testing ("AST") directly from positive blood culture ("PBC") bottles and bacterial isolated colonies ("Isolates") to report accurate results within 4.5 hours, on average.
It is estimated by the World Health Organization, Sepsis affects an estimated 49 million1 people globally each year, causing an estimated 11 million1 deaths of which an estimated 1.32 million are attributed to bacterial antimicrobial resistance. Additionally, Sepsis is the number one cost to the US healthcare system with an annual estimated expense of $62 billion3.&nbsp;By delivering rapid AST results, patients with serious infections can be put on targeted antimicrobial therapy to improve patient outcomes, cut hospital costs, and reduce antimicrobial resistance.

Accelerate Diagnostics Announces Completion Of Its WAVE Pre-Clinical Trial Designed To Deliver Rapid Antimicrobial Susceptibility Testing Directly From Positive Blood Culture Bottles And Bacterial Isolated Colonies To Report Accurate Results Within 4.5 Hours, On Average

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares increased by 9.01% to $1.39. The market value of their outstanding shares is at $30.6 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock increased by 8.28% to $1.83. The company's market cap stands at $4.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) shares fell 26.5% to $3.38 during Thursday's after-market session. The market value of their outstanding shares is at $91.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock decreased by 10.64% to $0.42. The company's market cap stands at $3.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 5.0% to $0.61. The market value of their outstanding shares is at $10.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 4.93% to $1.93. The market value of their outstanding shares is at $1.9 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 4.89% to $0.76. The company's market cap stands at $19.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 4.88% to $0.39. The company's market cap stands at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

BIOR

BMRA

EVOK

GNLX

GOVX

HLTH

ONMD

PPBT

TIVC

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock increased by 84.3% to $2.34 during Tuesday's regular session. The market value of their outstanding shares is at $10.2 million. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) shares increased by 28.6% to $5.53. The company's market cap stands at $149.2 million. </li>
<li>Novo Integrated Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVOS#NASDAQ">NVOS</a>) shares moved upwards by 24.55% to $0.54. The market value of their outstanding shares is at $10.3 million. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares rose 23.93% to $1.14. The company's market cap stands at $12.1 million. </li>
<li>Xylo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XYLO#NASDAQ">XYLO</a>) shares rose 21.98% to $2.33. The market value of their outstanding shares is at $4.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares increased by 16.25% to $1.02. The market value of their outstanding shares is at $22.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) stock fell 32.8% to $0.41 during Tuesday's regular session. The company's market cap stands at $41.4 million. </li>
<li>American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) shares declined by 27.76% to $1.9. The company's market cap stands at $19.3 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares fell 25.44% to $0.1. The market value of their outstanding shares is at $3.4 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) stock fell 25.13% to $0.12. The market value of their outstanding shares is at $7.8 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares decreased by 20.67% to $0.18. The company's market cap stands at $2.8 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares fell 20.4% to $6.21. The company's market cap stands at $8.5 million. As per the news, the Q1 earnings report came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKAN

AONC

BDRX

BNOX

DARE

GTBP

NVOS

SCPX

SNOA

XYLO

12 Health Care Stocks Moving In Tuesday's Intraday Session

Accelerate Diagnostics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axdx#NASDAQ">AXDX</a>) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.70 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -22.22%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of $0.62 per share when it actually produced a loss of $0.89, delivering a surprise of -43.55%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Accelerate Diagnostics, which belongs to the Zacks Medical - Instruments industry, posted revenues of $2.92 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 2.63%. This compares to year-ago revenues of $2.81 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock&#39;s immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management&#39;s commentary on the earnings call.
Accelerate Diagnostics shares have lost about 77% since the beginning of the year versus the S&amp;P 500&#39;s gain of 8.8%.
What&#39;s Next for Accelerate Diagnostics?
While Accelerate Diagnostics has underperformed the market so far this year, the question that comes to investors&#39; minds is: what&#39;s next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company&#39;s earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Accelerate Diagnostics: unfavorable. While the magnitude and direction of estimate revisions could change following the company&#39;s just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.56 on $3 million in revenues for the coming quarter and -$2.27 on $12.17 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Pacific Biosciences of California (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacb#NASDAQ">PACB</a>), another stock in the same industry, has yet to report results for the quarter ended March 2024. The results are expected to be released on May 9.
This maker of genetic analysis technology is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +16.1%. The consensus EPS estimate for the quarter has been revised 2.7% higher over the last 30 days to the current level.
Pacific Biosciences of California&#39;s revenues are expected to be $38.78 million, down 0.3% from the year-ago quarter.
<a href="https://www.zacks.com/stock/news/2270977/accelerate-diagnostics-axdx-reports-q1-loss-misses-revenue-estimates?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_4-2270977">To read this article on Zacks.com click here.</a>

Penny Stocks

Small Cap

Markets

Trading Ideas

PACB

Accelerate Diagnostics Reports Q1 Loss, Misses Revenue Estimates

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.88) per share which missed the analyst consensus estimate of $(0.72) by 22.22 percent. This is a 48.54 percent increase over losses of $(1.71) per share from the same period last year. The company reported quarterly sales of $2.921 million which missed the analyst consensus estimate of $3.000 million by 2.63 percent. This is a 3.88 percent increase over sales of $2.812 million the same period last year.

Accelerate Diagnostics Q1 2024 GAAP EPS $(0.88) Misses $(0.72) Estimate, Sales $2.921M Miss $3.000M Estimate

Craig-Hallum analyst Alexander Nowak maintains Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) with a Hold and lowers the price target from $2 to $1.

Price Target

Analyst Ratings

Craig-Hallum Maintains Hold on Accelerate Diagnostics, Lowers Price Target to $1

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Accelerate Diagnostics missed estimated earnings by -44.0%, reporting an EPS of $-0.89 versus an estimate of $-0.62.
Revenue was up $55 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.11 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Accelerate Diagnostics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.07</td>
<td>-1.40</td>
<td>-1.4</td>
<td>-1.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.18</td>
<td>-1.31</td>
<td>-1.7</td>
<td>-1.5</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.53M</td>
<td>3.60M</td>
<td>3.35M</td>
<td>2.87M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.30M</td>
<td>2.92M</td>
<td>2.81M</td>
<td>2.97M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Accelerate Diagnostics <a href="https://www.benzinga.com/quote/AXDX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Accelerate Diagnostics Q4 Earnings

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.62) by 43.55 percent. This is a 493.33 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $3.03 million which missed the analyst consensus estimate of $3.45 million by 12.26 percent. This is a 1.85 percent increase over sales of $2.97 million the same period last year.

Accelerate Diagnostics Q4 EPS $(0.89) Misses $(0.62) Estimate, Sales $3.03M Miss $3.45M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Universal Stainless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAP#NASDAQ">USAP</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million.
&bull; Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $158.50 million.
&bull; MSC Industrial Direct Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) is estimated to report quarterly earnings at $1.16 per share on revenue of $946.55 million.
&bull; Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $33.03 billion.
&bull; Data Storage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTST#NASDAQ">DTST</a>) is projected to report earnings for its fourth quarter.
&bull; Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) is likely to report quarterly loss at $1.68 per share on revenue of $1.71 million.
&bull; Atour Lifestyle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAT#NASDAQ">ATAT</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $168.26 million.
&bull; CNFinance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNF#NYSE">CNF</a>) is likely to report quarterly earnings at $0.01 per share on revenue of $65.41 million.
&bull; BRP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOOO#NASDAQ">DOOO</a>) is estimated to report quarterly earnings at $1.92 per share on revenue of $2.05 billion.
&bull; OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $26.47 million.
&bull; Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $985.30 million.
&bull; Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) is projected to report earnings for its fourth quarter.
&bull; Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is expected to report earnings for its fourth quarter.
&bull; DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is projected to report quarterly loss at $0.54 per share on revenue of $3.57 million.
&bull; Cheche Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCG#NASDAQ">CCG</a>) is expected to report earnings for its fourth quarter.
&bull; Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is projected to report earnings for its fourth quarter.
&bull; Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is projected to report earnings for its fourth quarter.
&bull; IM Cannabis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCC#NASDAQ">IMCC</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $10.45 million.
&bull; Smart Share Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EM#NASDAQ">EM</a>) is expected to report earnings for its fourth quarter.
&bull; 36KR Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRKR#NASDAQ">KRKR</a>) is projected to report earnings for its fourth quarter.
&bull; 22nd Century Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $17.10 million.
&bull; China Automotive Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAAS#NASDAQ">CAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; REX American Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REX#NYSE">REX</a>) is expected to report quarterly earnings at $0.68 per share on revenue of $190.26 million.
&bull; D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) is projected to report quarterly loss at $0.10 per share on revenue of $4.73 million.
&bull; Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is expected to report quarterly loss at $0.25 per share on revenue of $23.66 million.
&bull; American Oncology Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) is estimated to report earnings for its fourth quarter.
&bull; Gold Royalty (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GROY#AMEX">GROY</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $1.90 million.
&bull; Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) is projected to report earnings for its fourth quarter.
&bull; BOS Better Online Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOSC#NASDAQ">BOSC</a>) is projected to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is estimated to report quarterly loss at $0.44 per share on revenue of $40 thousand.
&bull; Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $11.10 million.
&bull; Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report quarterly loss at $0.08 per share on revenue of $63.50 million.
&bull; Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) is expected to report earnings for its fourth quarter.
&bull; Pineapple Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $20.40 million.
&bull; Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is projected to report quarterly earnings at $1.95 per share on revenue of $408.18 million.
&bull; Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) is estimated to report earnings for its fourth quarter.
&bull; Danimer Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNMR#NYSE">DNMR</a>) is projected to report quarterly loss at $0.38 per share on revenue of $11.33 million.
&bull; Dare Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DARE#NASDAQ">DARE</a>) is expected to report quarterly loss at $0.10 per share on revenue of $1.79 million.
&bull; Intellinetics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INLX#AMEX">INLX</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $4.10 million.
&bull; Shapeways Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) is expected to report quarterly loss at $0.95 per share on revenue of $9.25 million.
&bull; NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) is expected to report earnings for its fourth quarter.
&bull; CVD Equipment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVV#NASDAQ">CVV</a>) is projected to report earnings for its fourth quarter.
&bull; Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) is expected to report quarterly loss at $5.60 per share on revenue of $3.00 million.
&bull; NexGel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXGL#NASDAQ">NXGL</a>) is projected to report quarterly loss at $0.11 per share on revenue of $1.38 million.
&bull; ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) is expected to report earnings for its fourth quarter.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is estimated to report quarterly loss at $0.27 per share on revenue of $11.74 million.
&bull; American Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREC#NASDAQ">AREC</a>) is projected to report quarterly loss at $0.04 per share on revenue of $2.20 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $12.62 million.
&bull; Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) is likely to report quarterly loss at $3.77 per share on revenue of $250 thousand.
&bull; Surf Air Mobility (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NYSE">SRFM</a>) is likely to report quarterly loss at $0.28 per share on revenue of $25.69 million.
&bull; Emeren Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $44.98 million.
&bull; P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.11 per share on revenue of $302.97 million.
&bull; Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) is estimated to report quarterly loss at $0.85 per share on revenue of $200 thousand.
&bull; Dyadic International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYAI#NASDAQ">DYAI</a>) is likely to report quarterly loss at $0.06 per share on revenue of $800 thousand.
&bull; Semtech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) is projected to report quarterly loss at $0.03 per share on revenue of $196.46 million.
&bull; Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) is likely to report quarterly loss at $0.08 per share on revenue of $274.83 million.
&bull; Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter.
&bull; Arcadia Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKDA#NASDAQ">RKDA</a>) is projected to report quarterly loss at $2.58 per share on revenue of $1.75 million.
&bull; Achieve Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHV#NASDAQ">ACHV</a>) is projected to report earnings for its fourth quarter.
&bull; Sharecare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHCR#NASDAQ">SHCR</a>) is expected to report quarterly loss at $0.06 per share on revenue of $114.99 million.
&bull; Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) is projected to report quarterly loss at $0.28 per share on revenue of $980 thousand.
&bull; Cepton (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPTN#NASDAQ">CPTN</a>) is expected to report quarterly loss at $0.74 per share on revenue of $2.46 million.
&bull; Vuzix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VUZI#NASDAQ">VUZI</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $2.14 million.
&bull; Aspira Womens Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWH#NASDAQ">AWH</a>) is estimated to report quarterly loss at $0.45 per share on revenue of $2.54 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $5.56 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is estimated to report quarterly loss at $0.62 per share on revenue of $3.45 million.
&bull; Wrap Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRAP#NASDAQ">WRAP</a>) is likely to report earnings for its fourth quarter.
&bull; Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) is projected to report quarterly loss at $0.06 per share on revenue of $58.19 million.
&bull; Leafly Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) is likely to report quarterly loss at $1.45 per share on revenue of $9.49 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACHV

ACNT

AFMD

AREC

ATAT

AZUL

BETR

BOSC

CAAS

CPTN

CURV

DLPN

DNMR

DOOO

DRIO

DTST

DYAI

FORA

GROY

HSDT

IMCC

IMNN

INLX

INMB

ITRM

JFIN

KRKR

LFLY

NAAS

NDRA

NRXP

NVVE

NXGL

OPRX

PEGY

PIII

PLSE

QBTS

RKDA

SHCR

SHIM

SHPW

SMTC

SRFM

TSAT

USAP

VUZI

WATT

WRAP

XPON

XXII

ZVRA

Earnings Scheduled For March 28, 2024

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Accelerate Diagnostics will report an earnings per share (EPS) of $-0.62. 
Accelerate Diagnostics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.11, which was followed by a 2.88% drop in the share price the next day.
Here's a look at Accelerate Diagnostics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.07</td>
<td>-1.40</td>
<td>-1.4</td>
<td>-1.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.18</td>
<td>-1.31</td>
<td>-1.7</td>
<td>-1.5</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>41.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711551682_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Accelerate Diagnostics were trading at $0.9603 as of March 26. Over the last 52-week period, shares are down 86.34%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AXDX/earnings">To track all earnings releases for Accelerate Diagnostics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of Accelerate Diagnostics's Earnings

Accelerate Diagnostics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NYSE">AXDX</a>) short percent of float has fallen 26.07% since its last report. The company recently reported that it has 448 thousand shares sold short, which is 2.58% of all regular shares that are available for trading. Based on its trading volume, it would take traders 24.74 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Accelerate Diagnostics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1706721311_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Accelerate Diagnostics has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Accelerate Diagnostics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Accelerate Diagnostics's peer group average for short interest as a percentage of float is 1.48%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Accelerate Diagnostics's Recent Short Interest

<h3>Gainers</h3>
<ul>
<li>SINTX Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares increased by 75.0% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $2.1 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock rose 10.0% to $0.33. The market value of their outstanding shares is at $17.4 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 7.39% to $0.25. The company's market cap stands at $1.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 6.66% to $1.6. The company's market cap stands at $51.6 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock moved upwards by 5.04% to $0.67. The market value of their outstanding shares is at $18.1 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares moved upwards by 5.0% to $1.47. The company's market cap stands at $29.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares decreased by 10.3% to $7.25 during Tuesday's after-market session. The market value of their outstanding shares is at $269.3 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock fell 10.22% to $3.08. The market value of their outstanding shares is at $125.3 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares fell 7.88% to $0.31. The market value of their outstanding shares is at $67.1 million. </li>
<li>Assure Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) stock declined by 7.45% to $0.23. The company's market cap stands at $1.5 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock decreased by 6.51% to $1.15. The company's market cap stands at $2.5 million. </li>
<li>Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) shares fell 5.7% to $1.49. The market value of their outstanding shares is at $20.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CELU

CNSP

GLTO

IONM

NCNA

PTPI

SINT

SLDB

SPRB

12 Health Care Stocks Moving In Tuesday's After-Market Session

Shares of TransCode Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnaz#NASDAQ">RNAZ</a>) fell sharply during Friday&rsquo;s session.
TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share.
TransCode Therapeutics shares dipped 24.3% to $0.8248 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Charge Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crge#NASDAQ">CRGE</a>) shares surged 105.4% to $0.2510.</li>
<li>Kaman Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kamn#NASDAQ">KAMN</a>) shares climbed 101.3% to $45.14 after the company announced it will be acquired by Arcline for $1.8 billion.</li>
<li>Mesa Air Group Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mesa#NASDAQ">MESA</a>) gained 70.4% to $1.09 as the company entered into new agreements with United Airlines for improved operating and financing terms.</li>
<li>Edgewise Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ewtx#NASDAQ">EWTX</a>) rose 37.3% to $13.30 after the company announced pricing of its $240 million underwritten offering of 21,818,182 shares at $11 per share.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pcsa#NASDAQ">PCSA</a>) climbed 34.2% to $0.2725. Processa Pharmaceuticals announced plans to expand the development of next generation capecitabine (NGC-Cap) into advanced or metastatic breast cancer beginning with next Phase 2 trial in breast cancer.</li>
<li>Tricon Residential Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcn#NYSE">TCN</a>) shares gained 28.2% to $11.06 Blackstone and Tricon Residential entered into an arrangement agreement under which Blackstone Real Estate Partners X together with Blackstone Real Estate Income Trust, Inc. will acquire all outstanding common shares of Tricon for $11.25 per share in cash.</li>
<li>Spirit Airlines, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/save#NYSE">SAVE</a>) jumped 24% to $7.06 after the company announced preliminary fourth-quarter and full year 2023 estimates, issued first-quarter 2024 guidance and said the merger agreement between the company and JetBlue &quot;remains in full force and effect.&quot;</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) climbed 23.1% to $383.31 after the company announced updated financial guidance for the second-quarter, which surpassed its previous outlook.</li>
<li>Allied Gaming &amp; Entertainment Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agae#NASDAQ">AGAE</a>) rose 20.6% to $1.1190.</li>
<li>Portage Biotech Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtg#NASDAQ">PRTG</a>) gained 19% to $1.14.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) gained 19% to $2.07.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shph#NASDAQ">SHPH</a>) gained 16.4% to $0.5185.</li>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) shares rose 14.2% to $0.1176. Treasure Global and AIO Synergy recently entered into a strategic alliance aimed at reshaping the landscape of artificial intelligence.</li>
<li>Silk Road Medical, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/silk#NASDAQ">SILK</a>) jumped 13.1% to $14.91 after Stifel upgraded the stock from Hold to Buy and raised its price target from $9 to $20.</li>
<li>Wayfair Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/w#NYSE">W</a>) jumped 11.6% to $56.81 after the company announced a workforce realignment plan, which includes a workforce reduction involving approximately 13% of its global workforce.</li>
<li>Bullfrog AI Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bfrg#NASDAQ">BFRG</a>) gained 10.6% to $4.30.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nams#NASDAQ">NAMS</a>) rose 10.5% to $19.44.</li>
<li>World Acceptance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wrld#NASDAQ">WRLD</a>) gained 10.2% to $134.00 following upbeat quarterly results.</li>
<li>Ally Financial Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ally#NYSE">ALLY</a>) gained 9.4% to $35.15. Synchrony Financial announced plans to acquire Ally Financial&#39;s point of sale financing business. Ally Financial also posted upbeat quarterly sales.</li>
<li>Cyngn Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) surged 8.8% to $0.1468 after gaining over 5% on Thursday.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) gained 8.1% to $1.86 after the FDA granted a Rare Pediatric Disease Designation to the company&rsquo;s Revascor&reg; for treating children with congenital heart disease.</li>
<li>WNS (Holdings) Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wns#NYSE">WNS</a>) rose 4.4% to $65.71. Needham analyst Mayank Tandon maintained WNS with a Buy and raised the price target from $80 to $85.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares fell 63.2% to $0.1384 as the company announced pricing of $7.0 million upsized underwritten public offering.</li>
<li>Azitra, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aztr#NYSE">AZTR</a>) dipped 31.8% to $1.3976 after the company filed for a firm commitment public offering of 3 million shares of common stock.</li>
<li>iRobot Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/irbt#NASDAQ">IRBT</a>) fell 30% to $16.53 following a report suggesting the EU plans to block Amazon&#39;s acquisition of the company.</li>
<li>Accelerate Diagnostics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axdx#NASDAQ">AXDX</a>) fell 27.1% to $1.17 after the company reported pricing of approximately $15 million public offering and private placement.</li>
<li>AST SpaceMobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) declined 24.3% to $3.15. AST SpaceMobile announced a $100 million offering of common stock. The company also announced a strategic investment from AT&amp;T Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>),</li>
<li>Alphabet Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/goog#NASDAQ">GOOG</a>) (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/googl#NASDAQ">GOOGL</a>) and Vodafone.</li>
<li>Agrify Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agfy#NASDAQ">AGFY</a>) dipped 21.9% to $1.0699. Agrify entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park.</li>
<li>Adagene Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adag#NASDAQ">ADAG</a>) fell 21.6% to $2.64.</li>
<li>BioCardia, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcda#NASDAQ">BCDA</a>) fell 20% to $0.46.</li>
<li>Volato Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/soar#NYSE">SOAR</a>) fell 17.2% to $2.1688.</li>
<li>Datasea Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtss#NASDAQ">DTSS</a>) shares fell 16.4% to $0.1140. Datasea announced plans for a 1-for-15 reverse stock split to regain compliance with Nasdaq minimum bid requirement.</li>
<li>Orgenesis Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orgs#NASDAQ">ORGS</a>) dipped 15.3% to $0.2711.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) fell 12.6% to $3.19.</li>
<li>Nkarta, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nktx#NASDAQ">NKTX</a>) fell 12.2% to $7.47.</li>
<li>Vision Marine Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vmar#NASDAQ">VMAR</a>) shares fell 11.5% to $0.7098. Vision Marine Technologies announced close of $3.0 million private placement of convertible preferred shares and warrants with Investissement Qu&eacute;bec.</li>
<li>Absci Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/absi#NASDAQ">ABSI</a>) dipped 11.3% to $3.2120.</li>
<li>Lithium Americas Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lac#NYSE">LAC</a>) fell 10.4% to $4.3650.</li>
<li>Celsius Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celh#NASDAQ">CELH</a>) fell 10% to $53.60 after B of A Securities downgraded the stock from Buy to Neutral and announced a $65 price target.</li>
<li>Hut 8 Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hut#NYSE">HUT</a>) dipped 9.4% to $6.45.</li>
<li>Lifezone Metals Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lzm#NYSE">LZM</a>) fell 9.3% to $6.37.</li>
<li>MorphoSys AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mor#NASDAQ">MOR</a>) fell 7.3% to $9.49 after falling 6% on Wednesday. Morgan Stanley analyst James Quigley, on Tuesday, downgraded MorphoSys from Overweight to Equal-Weight.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htz#NASDAQ">HTZ</a>) declined 6.6% to $8.40 after Jefferies downgraded the stock from Buy to Hold and lowered its price target from $12 to $8.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) shares fell 6.1% to $2.0188. Esperion priced its $85.1 million public offering of 56.7 million common share at $1.50 per share.</li>
<li>Chegg, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/chgg#NYSE">CHGG</a>) shares fell 6.1% to $9.45. Goldman Sachs analyst Eric Sheridan downgraded Chegg from Neutral to Sell and lowered the price target from $10 to $8.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36690939/jim-cramer-predicts-a-terrific-year-for-this-manufacturer-and-as-for-u-haul-im-fine-with"> Jim Cramer Predicts A &#39;Terrific Year&#39; For This Manufacturer, And As For U-Haul? &#39;I&#39;m Fine With It&#39;</a>

Intraday Update

ABSI

ADAG

AGAE

AGFY

ALLY

ASTS

AZTR

BCDA

BFRG

CELH

CHGG

CISS

CRGE

DTSS

ESPR

EWTX

GOOG

GOOGL

IRBT

KAMN

MESA

MESO

Morgan Stanley Capital Protected Notes for S&P 500 Index

NAMS

NKTX

ORGS

PCSA

PRTG

RNAZ

SAVE

SHPH

SILK

SMCI

SOAR

VMAR

WRLD

Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Edgewise Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>) stock moved upwards by 35.8% to $13.15 during Friday's regular session. The market value of their outstanding shares is at $834.8 million. </li>
<li>Bullfrog AI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRG#NASDAQ">BFRG</a>) shares moved upwards by 32.13% to $5.14. The company's market cap stands at $31.3 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) shares moved upwards by 23.51% to $0.55. The company's market cap stands at $8.7 million. </li>
<li>NightHawk Biosciences (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHWK#AMEX">NHWK</a>) shares increased by 16.58% to $0.42. The market value of their outstanding shares is at $10.9 million. </li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) shares rose 14.3% to $14.02. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) shares increased by 11.73% to $3.56. The market value of their outstanding shares is at $242.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock declined by 34.0% to $1.06 during Friday's regular session. The company's market cap stands at $15.4 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares fell 31.71% to $1.4. The market value of their outstanding shares is at $16.9 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 28.49% to $0.78. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 23.94% to $0.44. The company's market cap stands at $10.3 million. </li>
<li>Adagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) stock fell 21.37% to $2.65. The market value of their outstanding shares is at $116.1 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock declined by 15.45% to $0.38. The market value of their outstanding shares is at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALVO

NHWK

TNYA

12 Health Care Stocks Moving In Friday's Intraday Session

Press Releases

Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results

Accelerate Diagnostics Scheduled Call to Review 2024 Second Quarter Results

Accelerate Diagnostics Announces a Successful Completion of its WAVE™ Pre-Clinical Trial

Accelerate Diagnostics Reports Second Quarter 2024 Financial Results

Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System

Accelerate Diagnostics Scheduled Call to Review 2024 Third Quarter Results

Accelerate Diagnostics Reports Third Quarter 2024 Financial Results

Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

Comments

Accelerate Diagnostics

Noticias

Últimas noticias sobre Accelerate Diagnostics (NASDAQ:AXDX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL